Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13001968 | 0.81 | HPGD (0.53) | NR3C2BRD4HPGDLMNASMN1; SMN2 | |
| SCHEMBL10294715 | 0.81 | HPGD (0.62) | NR3C2HPGDLMNASMN1; SMN2HTT | |
| SCHEMBL8274370 | 0.81 | NR3C2 (0.57) | NR3C2BRD4HPGDLMNASMN1; SMN2 | |
| SCHEMBL13884318 | 0.80 | ALDH1A1 (0.42) | LMNASMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL10294867 | 0.80 | HPGD (0.47) | NR3C2BRD4HPGDLMNASMN1; SMN2 | |
| SCHEMBL18649047 | 0.78 | NR3C2 (0.54) | NR3C2BRD4HPGDLMNASMN1; SMN2 | |
| SCHEMBL20782198 | 0.78 | ADRA2A (0.52) | NR3C2BRD4HPGDLMNASMN1; SMN2 | |
| SCHEMBL10294181 | 0.78 | HTR6 (0.59) | HPGDLMNASMN1; SMN2 | |
| SCHEMBL10191952 | 0.78 | HPGD (0.53) | BRD4HPGDLMNASMN1; SMN2HTT | |
| SCHEMBL10294174 | 0.77 | NR3C2 (0.45) | NR3C2BRD4HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | NR3C2 55/4885BRD4 1262/4885HPGD 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.